Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
2017
Oncogenic RAS mutants are key anti-cancer targets as KRas mutations are very frequent in human cancers. Here, the authors engineer a cytosol-penetrating anti-Ras antibody and demonstrate its ability to block RAS-effector protein interactions inhibiting tumour growth of Ras mutant-driven cancers.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
63
References
84
Citations
NaN
KQI